nach oben

Erschienen in:

01.08.2008 | Original Article

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors

verfasst von: Kostas Kalbakis, Periklis Pappas, Charalambos Kouroussis, Lambros Vamvakas, Antonia Kalykaki, Nikolaos Vardakis, Martha Nikolaidou, Marios Marselos, Vassilis Georgoulias, Dimitris Mavroudis

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the maximum tolerated doses (MTD) and the dose-limiting toxicities (DLT) of the combination of pegylated liposomal doxorubicin (PEG-LD), paclitaxel and oxaliplatin (L-OHP) administered every 2 weeks in patients with advanced solid tumors.

Methods

Thirty-nine pretreated patients with advanced solid tumors received escalated doses of PEG-LD (10–16 mg/m²), paclitaxel (100–120 mg/m²) and L-OHP (50–70 mg/m²) every 2 weeks. As one cycle of treatment was considered the administration of both drugs on days 1 and 15 of a 4-week cycle.

Results

The MTDs were PEG-LD 14 mg/m², paclitaxel 120 mg/m² and L-OHP 70 mg/m². Neutropenia was the DLT in all but one case with only one episode of febrile neutropenia and no toxic deaths. Four (4%) and 13 (12%) cycles were complicated by grades 4 and 3 neutropenia, respectively. Grades 2–3 fatigue and neurotoxicity occurred in 13 and 12% of cycles, respectively. Responses were observed in patients with breast, endometrial and ovarian carcinomas.

Conclusions

This is a quite well-tolerated regimen which merits further evaluation in phase II studies.

Raitanen M, Rantanen V, Kulmala J, Helenius H, Grenman R, Grenman S 2002) Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. Int J Cancer 100:238–243PubMedCrossRef

Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet 357:1478–1484PubMedCrossRef

Hamilton A, Hortobagyi G (2005) Chemotherapy: what progress in the last 5 years? J Clin Oncol 23:1760–1775PubMedCrossRef

Kouroussis C, Kakolyris S, Mavroudis D, Androulakis N, Kalbakis K, Agelaki S, Sarra E, Souglakos J, Christodoulakis M, Samonis G, Georgoulias V (2001) A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. Am J Clin Oncol 24:404–407PubMedCrossRef

Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983–5992PubMedCrossRef

Cvitkovic E (1998) Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 77:8–11PubMed

Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M (2005) Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 35:453–463PubMedCrossRef

Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaïne MA, Itzhaki M, Marty M, Extra JM (1999) Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 10:1125–1128PubMedCrossRef

Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C et al (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688–2699PubMed

10.

Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72–78PubMedCrossRef

11.

O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449PubMedCrossRef

12.

Mavroudis D, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V (2002) Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors. Oncology 62:216–222PubMedCrossRef

13.

Briasoulis E, Karavasilis V, Tzamakou E, Rammou D, Soulti K, Piperidou C, Pavlidis N (2004) Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 53:452–457PubMedCrossRef

14.

Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J (1998) Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 705:159–164PubMedCrossRef

15.

Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17:1751–1759PubMed

16.

Gregory RK, Hill ME, Moore J, A’Hern RP, Johnston SR, Blake P, Shephard J, Barton D, Gore ME (2000) Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. Eur J Cancer 36:503–507PubMedCrossRef

17.

Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037–1047PubMedCrossRef

18.

Ichiki M, Gohara R, Fujiki R, Hoashi S, Rikimaru T, Aizawa H (2003) Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 52:67–72PubMedCrossRef

19.

Desai PB, Duan JZ, Zhu YW, Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417–424PubMed

20.

Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G (2006) Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol 23:147–160PubMedCrossRef

21.

Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW (1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15:1953–1964PubMed

22.

Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE et al (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692–1703PubMed

23.

Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A (2002) Comparative pharmacokinetics of unbound paclitaxel during 1-hour and 3-hour infusions. J Clin Oncol 20:574–581PubMedCrossRef

Titel: A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors
verfasst von: Kostas Kalbakis
Periklis Pappas
Charalambos Kouroussis
Lambros Vamvakas
Antonia Kalykaki
Nikolaos Vardakis
Martha Nikolaidou
Marios Marselos
Vassilis Georgoulias
Dimitris Mavroudis
Publikationsdatum: 01.08.2008
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2008
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0624-3

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors